-
Gilead to Acquire Remaining Worldwide Rights of Trodelvy®
– Gilead will Assume Responsibility for Clinical Development and Commercialization in Greater China and South Korea, among Other Asian Markets – FOSTER CITY, Calif.--(BUSINESS WIRE)-- Gilead Sciences, ...
-
U.S. FDA Grants Accelerated Approval to Trodelvy® for the Treatment of Metastatic Urothelial Cancer
– Accelerated Approval Granted for Locally Advanced or Metastatic Urothelial Cancer Following a Platinum-Containing Chemotherapy and a PD-1/PD-L1 Inhibitor – – New Indication Marks ...
-
FOSTER CITY, Calif.--(BUSINESS WIRE)-- Gilead Sciences, Inc. (Nasdaq: GILD) today announced the presentation of new research on its first-in-class antibody-drug conjugate (ADC) Trodelvy® (sacituzumab ...
-
Gilead to Present New Trodelvy® Data at the IASLC 2024 World Conference on Lung Cancer
-Data Span Multiple Types of Lung Cancer and Lines of Therapy- ...
-
U.S. FDA Approves Trodelvy® in Pre-treated HR+/HER2- Metastatic Breast Cancer
-- First Trop-2 Directed ADC to Demonstrate Overall Survival Benefit in HR+/HER2- Metastatic Breast Cancer Patients who had Received Prior Endocrine-based Therapy and at Least Two Chemotherapies -- -- ...
-
European Commission Approves Gilead’s Trodelvy® For Pre-Treated HR+/HER2- Metastatic Breast Cancer
-- Approval Based on Clinically Meaningful Overall Survival Benefit Demonstrated in the TROPiCS-02 Study in Pre-Treated HR+/HER2- (IHC 0, IHC 1+ or IHC 2+/ISH–) Metastatic Breast Cancer ...
-
-- Recommendation Based on the TROPiCS-02 Study Showing Trodelvy Demonstrated Statistically Significant and Clinically Meaningful Overall Survival in Pre-Treated HR+/HER2- (IHC 0, IHC 1+ ...
-
– Trodelvy – the First Trop-2-Directed ADC – Delivers a Durable and Clinically Meaningful 3.3 Month Improvement in Median Overall Survival vs. Comparator Chemotherapy in Phase ...
-
FOSTER CITY, Calif.--(BUSINESS WIRE)-- Gilead Sciences, Inc. (Nasdaq: GILD) today announced it will present new data at San Antonio Breast Cancer Symposium (SABCS) 2023, supporting the use of Trodelvy® ...
-
– Oral Presentati on Highlights Trodelvy Efficacy of 13.5 Months Overall Survival in Pati ents with Platinum-Ineligible Metastatic UC After Checkpoint Inhibitor Therapy ...